Search

Your search keyword '"Bechstein WO"' showing total 861 results
Start Over Author "Bechstein WO"
861 results on '"Bechstein WO"'

2. Multidrug-resistant organisms predispose to relapsing cholangitis in liver graft recipients with stenosis of the biliary anastomosis

Author

Ferstl, PG, additional, Bremer, K, additional, Filmann, N, additional, Queck, A, additional, Weiler, N, additional, Trebicka, J, additional, Welker, MW, additional, Waidmann, O, additional, Bechstein, WO, additional, Kempf, VAJ, additional, Hogardt, M, additional, Zeuzem, S, additional, Friedrich-Rust, M, additional, and Walter, D, additional

Published
2021
Full Text
View/download PDF

3. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors

Author

Schnitzbauer, A, Filmann, N, Adam, R, Bachellier, P, Bechstein, W, Becker, T, Bhoori, S, Bilbao, I, Brockmann, J, Burra, P, Chazoullieres, O, Cillo, U, Colledan, M, Duvoux, C, Ganten, T, Gugenheim, J, Heise, M, van Hoek, B, Jamieson, N, de Jong, K, Klein, C, Klempnauer, J, Kneteman, N, Lerut, J, Makisalo, H, Mazzaferro, V, Mirza, D, Nadalin, S, Neuhaus, P, Pageaux, G, Pinna, A, Pirenne, J, Pratschke, J, Powel, J, Rentsch, M, Rizell, M, Rossi, G, Rostaing, L, Roy, A, Scholz, T, Settmacher, U, Soliman, T, Strasser, S, Soderdahl, G, Troisi, R, Turrion, V, Schlitt, H, Geissler, E, Schnitzbauer AA, Filmann N, Adam RP, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullieres O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Makisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy AP, Scholz T, Settmacher U, Soliman T, Strasser S, Soderdahl G, Troisi RI, Turrion VS, Schlitt HJ, Geissler EK, Schnitzbauer, A, Filmann, N, Adam, R, Bachellier, P, Bechstein, W, Becker, T, Bhoori, S, Bilbao, I, Brockmann, J, Burra, P, Chazoullieres, O, Cillo, U, Colledan, M, Duvoux, C, Ganten, T, Gugenheim, J, Heise, M, van Hoek, B, Jamieson, N, de Jong, K, Klein, C, Klempnauer, J, Kneteman, N, Lerut, J, Makisalo, H, Mazzaferro, V, Mirza, D, Nadalin, S, Neuhaus, P, Pageaux, G, Pinna, A, Pirenne, J, Pratschke, J, Powel, J, Rentsch, M, Rizell, M, Rossi, G, Rostaing, L, Roy, A, Scholz, T, Settmacher, U, Soliman, T, Strasser, S, Soderdahl, G, Troisi, R, Turrion, V, Schlitt, H, Geissler, E, Schnitzbauer AA, Filmann N, Adam RP, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullieres O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Makisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy AP, Scholz T, Settmacher U, Soliman T, Strasser S, Soderdahl G, Troisi RI, Turrion VS, Schlitt HJ, and Geissler EK

Abstract

Objective: The aim of this study was to evaluate the survival benefit of sirolimus in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory analysis of the SiLVER-trial). Summary and Background Data: Patients receiving LT) for HCC are at a high risk for tumor recurrence. Calcineurin inhibitors have shown evidence to promote cancer growth, whereas mammalian target of rapamycin (mTOR) inhibitors like sirolimus have anticancer effects. In the SiLVER-trial (Clinicaltrials.gov:NCT00355862), the effect of sirolimus on the recurrence of HCC after LTwas investigated in a prospective randomized trial. Although the primary endpoint of improved disease-free survival (DFS) with sirolimus was not met, outcomes were improved for patients in the sirolimus-treatment arm in the first 3 to 5 years. To learn more about the key variables, a multivariate analysis was performed on the SiLVER-trial data. Patients and Methods: Data from 508 patients of the intention-to-treat analysis were included in exploratory univariate and multivariate models for overall survival (OS), DFS and a competing risk analysis for HCC recurrence. Results: Sirolimus use for >= 3 months after LT for HCC independently reduced the hazard for death in the multivariate analysis [hazard ratio (HR): 0.7 (95% confidence interval, CI: 0.52-0.96, P = 0.02). Most strikingly, patients with an alpha-fetoprotein (AFP) >= 10 ng/mL and having used sirolimus for >= 3 months, benefited most with regard to OS, DFS, and HCC-recurrence (HR: 0.49- 0.59, P = 0.0079- 0.0245). Conclusions: mTOR-inhibitor treatment with sirolimus for >= 3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients. Clinical Trial Registration: EudraCT: 2005-005362-36 Clinicaltrials.gov: NCT00355862.

Published
2020

8. CYP24A1 Haplotypes Are Associated with Differentiated Thyroid Carcinoma.

Author

Penna-Martinez, M, primary, Ramos-Lopez, E, additional, Stern, J, additional, Kahles, H, additional, Hinsch, N, additional, Hansmann, M-L, additional, Selkinski, I, additional, Gruenwald, F, additional, Vorlaender, C, additional, Bechstein, WO, additional, Zeuzem, S, additional, Holzer, K, additional, and Badenhoop, K, additional

Published
2010
Full Text
View/download PDF

9. Skeletal muscle index by CT correlates with kinetic growth and resectability after PVE

Author

Heil, J, additional, Heid, F, additional, Björnsson, B, additional, Bechstein, WO, additional, Brismar, T, additional, Carling, U, additional, Fretland, Å, additional, Hana, RA, additional, Linke, R, additional, Meyer, Y, additional, Nawawi, A, additional, Schnitzbauer, AA, additional, Sparrelid, E, additional, Metrakos, P, additional, Verhoef, K, additional, and Schadde, E, additional

Published
2020
Full Text
View/download PDF

10. The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study

Author

Trunecka, P, Klempnauer, J, Bechstein, Wo, Pirenne, J, Bennet, W, Zhao, A, Isoniemi, H, Rostaing, L, Settmacher, U, Monch, C, Brown, M, Undre, N, Kazeem, G, Tisone, G, and DIAMOND study group

Subjects
Adult, Graft Rejection, Male, ACUTE KIDNEY INJURY, Kidney, Kidney Function Tests, Tacrolimus, Kidney Failure, Humans, FAILURE, ddc:610, Chronic, Aged, Original Paper, Transplantation, Science & Technology, MORTALITY, Age Factors, Glomerular Filtration Rate, Immunosuppressive Agents, Liver Transplantation, Delayed-Action Preparations, Female, Kidney Failure, Chronic, Middle Aged, Mycophenolic Acid, Tissue Donors, Transplant Recipients, DYSFUNCTION, Settore MED/18, MELD, surgical procedures, operative, RISK-FACTORS, Surgery, Life Sciences & Biomedicine
Abstract

BACKGROUND The DIAMOND study of de novo liver transplant patients showed that prolonged-release tacrolimus exposure in the acute post-transplant period maintained renal function over 24 weeks of treatment. To assess these findings further, we performed a post-hoc analysis in patients according to baseline kidney function, Model for End-stage Liver Disease [MELD] scores, and donor age. MATERIAL AND METHODS Patients received prolonged-release tacrolimus (initial-dose, Arm 1: 0.2 mg/kg/day, Arm 2: 0.15-0.175 mg/kg/day, Arm 3: 0.2 mg/kg/day delayed until Day 5), mycophenolate mofetil and 1 steroid bolus. Arms 2 and 3 also received basiliximab. The recommended tacrolimus target trough levels to Day 42 post-transplantation were 5-15 ng/mL in all arms. In this post-hoc analysis, change in renal outcome, based on estimated glomerular filtration rate (eGFR), Modified Diet in Renal Disease-4 (MDRD4), values from baseline to Week 24 -post-transplantation, were assessed according to baseline patient factors: eGFR (≥60 and ˂60 mL/min/1.73 m²), MELD score (˂25 and ≥25) and donor age (˂50 and ≥50 years). RESULTS Baseline characteristics were comparable (Arms 1-3: n=283, n=287, n=274, respectively). Patients with baseline renal function, eGFR ≥60 mL/min/1.73 m², experienced a decrease in eGFR in all tacrolimus treatment arms. In patients with lower baseline renal function (eGFR ˂60 mL/min/1.73 m²), an advantage for renal function was observed with both the early lower-dose and delayed higher-dose tacrolimus regimens compared with the early introduction of higher-dose tacrolimus. At Week 24, renal function was higher in the early-lower tacrolimus arm with older donors, and the delayed higher-dose tacrolimus arm with younger donors, both compared with early higher-dose tacrolimus. CONCLUSIONS Pre-transplantation factors, such as renal function and donor age, could guide the choice of prolonged-release tacrolimus regimen following liver transplantation. ispartof: ANNALS OF TRANSPLANTATION vol:24 pages:319-327 ispartof: location:United States status: published

Published
2019

11. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial.

Author

Garlipp, B, Gibbs, P, Van Hazel, GA, Jeyarajah, R, Martin, RCG, Bruns, CJ, Lang, H, Manas, DM, Ettorre, GM, Pardo, F, Donckier, V, Benckert, C, van Gulik, TM, Goéré, D, Schoen, M, Pratschke, J, Bechstein, WO, de la Cuesta, AM, Adeyemi, S, Ricke, J, Seidensticker, M, Garlipp, B, Gibbs, P, Van Hazel, GA, Jeyarajah, R, Martin, RCG, Bruns, CJ, Lang, H, Manas, DM, Ettorre, GM, Pardo, F, Donckier, V, Benckert, C, van Gulik, TM, Goéré, D, Schoen, M, Pratschke, J, Bechstein, WO, de la Cuesta, AM, Adeyemi, S, Ricke, J, and Seidensticker, M

Abstract

BACKGROUND: Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. METHODS: Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by three or five (of 14) expert hepatopancreatobiliary surgeons for resectability. Reviewers were blinded to one another, treatment assignment, extrahepatic disease status, and information on clinical and scanning time points. Technical resectability was defined as at least 60 per cent of reviewers (3 of 5, or 2 of 3) assessing a patient's liver metastases as surgically removable. RESULTS: Some 472 patients were evaluable (SIRT, 244; control, 228). There was no significant baseline difference in the proportion of technically resectable liver metastases between SIRT (29, 11·9 per cent) and control (25, 11·0 per cent) arms (P = 0·775). At follow-up, significantly more patients in both arms were deemed technically resectable compared with baseline: 159 of 472 (33·7 per cent) versus 54 of 472 (11·4 per cent) respectively (P = 0·001). More patients were resectable in the SIRT than in the control arm: 93 of 244 (38·1 per cent) versus 66 of 228 (28·9 per cent) respectively (P < 0·001). CONCLUSION: Adding SIRT to chemotherapy may improve the resectability of unresectable CRLM.

Published
2019

12. Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An Extension Study

Author

Adam, R, Karam, V, Cailliez, V, Trunecka, P, Samuel, D, Tisone, G, Nemec, P, Soubrane, O, Schneeberger, S, Gridelli, B, Bechstein, W, Risaliti, A, Line, P, Vivarelli, M, Rossi, M, Pirenne, J, Klempnauer, J, Rummo, A, Di Benedetto, F, Zieniewicz, K, Troisi, R, Paul, A, Vali, T, Kollmar, O, Boudjema, K, Hoti, E, Colledan, M, Pratschke, J, Lang, H, Popescu, I, Ericzon, B, Strupas, K, De Simone, P, Kochs, E, Heyd, B, Gugenheim, J, Pinna, A, Bennet, W, Kazimi, M, Bachellier, P, Wigmore, S, Rasmussen, A, Clavien, P, Hidalgo, E, O'Grady, J, Zamboni, F, Kilic, M, Duvoux, C, Adam R, Karam V, Cailliez V, Trunecka P, Samuel D, Tisone G, Nemec P, Soubrane O, Schneeberger S, Gridelli B, Bechstein WO, Risaliti A, Line PD, Vivarelli M, Rossi M, Pirenne J, Klempnauer JL, Rummo A, Di Benedetto F, Zieniewicz K, Troisi R, Paul A, Vali T, Kollmar O, Boudjema K, Hoti E, Colledan M, Pratschke J, Lang H, Popescu I, Ericzon BG, Strupas K, De Simone P, Kochs E, Heyd B, Gugenheim J, Pinna AD, Bennet W, Kazimi M, Bachellier P, Wigmore SJ, Rasmussen A, Clavien PA, Hidalgo E, O'Grady JG, Zamboni F, Kilic M, Duvoux C, Adam, R, Karam, V, Cailliez, V, Trunecka, P, Samuel, D, Tisone, G, Nemec, P, Soubrane, O, Schneeberger, S, Gridelli, B, Bechstein, W, Risaliti, A, Line, P, Vivarelli, M, Rossi, M, Pirenne, J, Klempnauer, J, Rummo, A, Di Benedetto, F, Zieniewicz, K, Troisi, R, Paul, A, Vali, T, Kollmar, O, Boudjema, K, Hoti, E, Colledan, M, Pratschke, J, Lang, H, Popescu, I, Ericzon, B, Strupas, K, De Simone, P, Kochs, E, Heyd, B, Gugenheim, J, Pinna, A, Bennet, W, Kazimi, M, Bachellier, P, Wigmore, S, Rasmussen, A, Clavien, P, Hidalgo, E, O'Grady, J, Zamboni, F, Kilic, M, Duvoux, C, Adam R, Karam V, Cailliez V, Trunecka P, Samuel D, Tisone G, Nemec P, Soubrane O, Schneeberger S, Gridelli B, Bechstein WO, Risaliti A, Line PD, Vivarelli M, Rossi M, Pirenne J, Klempnauer JL, Rummo A, Di Benedetto F, Zieniewicz K, Troisi R, Paul A, Vali T, Kollmar O, Boudjema K, Hoti E, Colledan M, Pratschke J, Lang H, Popescu I, Ericzon BG, Strupas K, De Simone P, Kochs E, Heyd B, Gugenheim J, Pinna AD, Bennet W, Kazimi M, Bachellier P, Wigmore SJ, Rasmussen A, Clavien PA, Hidalgo E, O'Grady JG, Zamboni F, Kilic M, and Duvoux C

Abstract

Background. We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. Methods. Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T. Overall, 13 088 patients were included from 44 European centers; propensity score-matched analyses comprised 3006 patients (PR-T: n = 1002; IR-T: n = 2004). Results. In multivariate analyses, IR-T-based immunosuppression was associated with reduced graft survival (risk ratio, 1.49; P = 0.0038) and patient survival (risk ratio, 1.40; P = 0.0215). There was improvement with PR-T versus IR-T in graft survival (83% versus 77% at 4 y, respectively; P = 0.005) and patient survival (85% versus 80%; P = 0.017). Patients converted from IR-T to PR-T after 1 month had a higher graft survival rate than patients receiving IR-T at last follow-up (P < 0.001), or started and maintained on PR-T (P = 0.019). One graft loss in 4 years was avoided for every 14.3 patients treated with PR-T versus IR-T. Conclusions. PR-T-based immunosuppression might improve long-term outcomes in liver transplant recipients than IR-T-based immunosuppression.

Published
2019

14. Multiresistente Erreger sind bei Patienten auf der Warteliste zur Lebertransplantation häufig nachweisbar und mit einer erhöhten postoperativen Letalität assoziiert

Author

Ferstl, P, additional, Heilgenthal, EM, additional, Bechstein, WO, additional, Schnitzbauer, AA, additional, Kempf, VA, additional, Hogardt, M, additional, Reinheimer, C, additional, Stephan, C, additional, Mutlak, H, additional, Filmann, N, additional, Weiler, N, additional, Waidmann, O, additional, Zeuzem, S, additional, and Welker, MW, additional

Published
2019
Full Text
View/download PDF

15. Überleben nach sekundärer Resektion von Lebermetastasen beim metastasierten kolorektalen Karzinom: Eine vergleichende Analyse der LICC-Studie mit historischen Kontrollen (CELIM, FIRE-3)

Author

Moehler, M, additional, Folprecht, G, additional, Heinemann, V, additional, Holch, J, additional, Maderer, A, additional, Kasper, S, additional, Hegewisch-Becker, S, additional, Schröder, J, additional, Overkamp, F, additional, Kullmann, F, additional, Bechstein, WO, additional, Vöhringer, M, additional, Öllinger, R, additional, Lordick, F, additional, Geißler, M, additional, Schulz-Abelius, A, additional, Linz, B, additional, Bernhard, H, additional, Schmidtmann, I, additional, and Schimanski, C, additional

Published
2019
Full Text
View/download PDF

16. R0-resection following chemotherapy or chemoradiation improves survival of primary inoperable pancreatic cancer patients. Interim results of the CONKO-007 prospective randomized multicenter trial

Author

Brunner, M, additional, Wittel, U, additional, Croner, R, additional, Ghadimi, M, additional, Jacobasch, L, additional, Neumann, U, additional, Reinacher-Schick, A, additional, Imhoff, D, additional, Böck, S, additional, Keilholz, L, additional, Oettle, H, additional, Hohenberger, W, additional, Bechstein, WO, additional, Uhl, W, additional, Pirkl, A, additional, Adler, W, additional, Semrau, S, additional, Lubgan, D, additional, Fietkau, R, additional, and Grützmann, R, additional

Published
2019
Full Text
View/download PDF

17. Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase-II-Studie zur adjuvanten Immuntherapie mit Tecemotid (L-BLP25) nach R0/R1 Resektion von Lebermetastasen beim kolorektalen Karzinom (LICC): Finale Ergebnisse

Author

Schimanski, C, additional, Lang, H, additional, Kasper, S, additional, Paul, A, additional, Hegewisch-Becker, S, additional, Schröder, J, additional, Gassel, HJ, additional, Overkamp, F, additional, Büsing, M, additional, Kullmann, F, additional, Dietl, KH, additional, Bechstein, WO, additional, Vöhringer, M, additional, Steurer, W, additional, Öllinger, R, additional, Lordick, F, additional, Heinemann, V, additional, Geißler, M, additional, Staib, L, additional, Schulz-Abelius, A, additional, Linz, B, additional, Bernhard, H, additional, Schoen, MR, additional, Greil, R, additional, Smith-Machnow, V, additional, Schmidtmann, I, additional, and Moehler, M, additional

Published
2019
Full Text
View/download PDF

18. Etablierung eines Chirurgenpanels zur Beurteilung der Nicht-Resektabilität von Pankreaskarzinomen vor Einschluss in die CONKO-Studie (EudraCT:2009 – 014476 – 21) – Eine aufwändige Maßnahme zur Qualitätssicherung in einer multizentrischen Studie

Author

Wittel, U, additional, Grützmann, R, additional, Bechstein, WO, additional, Belyaev, O, additional, Uhl, W, additional, Ghadimi, M, additional, Hopt, U, additional, Schmidt, A, additional, Pirkl, A, additional, Lubgan, D, additional, Hohenberger, W, additional, Oettle, H, additional, Fietkau, R, additional, and Golcher, H, additional

Published
2018
Full Text
View/download PDF

19. Prognostische Faktoren für das intrahepatische Cholangiokarzinom in einer deutschen multizentrischen Kohorte in 512 Indikationen für eine kurative Resektion

Author

Schnitzbauer, AA, additional, Eberhard, J, additional, Bartsch, F, additional, Brunner, S, additional, Ceyhan, GO, additional, Friess, H, additional, Hecker, A, additional, Li, J, additional, Oldhafer, K, additional, Rahbari, N, additional, Rauchfuss, F, additional, Schlitt, HJ, additional, Settmacher, U, additional, Stavrou, G, additional, Weitz, J, additional, Lang, H, additional, Bechstein, WO, additional, and Rückert, F, additional

Published
2018
Full Text
View/download PDF

22. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group

Author

Neuberger, JM, Bechstein, WO, Kuypers, DRJ, Burra, P, Citterio, F, van der Geest, S, Duvoux, C, Jardine, A G, Kamar, N, Kramer, BK, Metselaar, Herold, Nevens, F, Pirenne, J, Rodriguez-Peralvarez, ML, Samuel, D, Schneeberger, S, Seron, D, Trunecka, P, Tisone, G, Gelder, Teun, Neuberger, JM, Bechstein, WO, Kuypers, DRJ, Burra, P, Citterio, F, van der Geest, S, Duvoux, C, Jardine, A G, Kamar, N, Kramer, BK, Metselaar, Herold, Nevens, F, Pirenne, J, Rodriguez-Peralvarez, ML, Samuel, D, Schneeberger, S, Seron, D, Trunecka, P, Tisone, G, and Gelder, Teun

Published
2017

23. Wie alt ist zu alt? Onkologische kolorektale Chirurgie bei Patienten über 65 Jahre

Author

Schreckenbach, T, Zeller, MV, El Youzouri, H, Bechstein, WO, and Woeste, G

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Lebenserwartung sowie die Inzidenz der kolorektalen Karzinome in den Industrienationen steigen stetig an. Diese Studie untersucht die Unterschiede in der postoperativen Morbidität und Letalität bei Patienten über 65 Jahre nach onkologischen kolorektalen Resektionen. [zum vollständigen Text gelangen Sie über die oben angegebene URL], 133. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2016
Full Text
View/download PDF

24. Bauchdeckenrekonstruktion bei kontaminierten Wundverhältnissen – Indikation für ein synthetisches oder biologisches Implantat?

Author

Woeste, G, Reinisch, A, Schreckenbach, T, and Bechstein, WO

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Verwendung eines synthetischen oder biologischen Implantates bei der Versorgung von komplexen Hernien in kontaminierten oder infizierten Gebieten (Ventral Hernia Working Group (VHWG) Grad 3 und 4) wird kontrovers gesehen. Umfragen unter Chirurgen in Deutschland zeigen eine deutliche [zum vollständigen Text gelangen Sie über die oben angegebene URL], 133. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2016
Full Text
View/download PDF

27. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial

Author

Götze, T, additional, Homann, N, additional, Schmalenberg, H, additional, Kopp, HG, additional, Haag, GM, additional, Luley, K, additional, Schmiegel, W, additional, Folprecht, G, additional, Probst, S, additional, Prasnikar, N, additional, Thuss-Patience, P, additional, Fischbach, W, additional, Trojan, J, additional, Koenigsmann, M, additional, Pauligk, C, additional, Kraus, T, additional, Battmann, A, additional, Paul, A, additional, Mönig, S, additional, Bechstein, WO, additional, Gaiser, T, additional, Tannapfel, A, additional, Jäger, E, additional, Schuler, M, additional, Lindig, U, additional, Pohl, M, additional, Kasper, S, additional, Hofheinz, RD, additional, and Al-Batran, SE, additional

Published
2017
Full Text
View/download PDF

30. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study

Author

TruneČka, P, Klempnauer, J, Bechstein, WO, Pirenne, Jacques, Friman, S, Zhao, A, Isoniemi, H, Rostaing, L, Settmacher, U, Mönch, C, Brown, M, Undre, N, Tisone, G, and on behalf of the DIAMOND† study group

Subjects
Graft Rejection, Male, immunosuppressant, Basiliximab, medicine.medical_treatment, immunosuppression/immune modulation, 030230 surgery, Liver transplantation, Kidney Function Tests, Postoperative Complications, 0302 clinical medicine, Bolus (medicine), Risk Factors, calcineurin inhibitor, Clinical endpoint, Immunology and Allergy, Pharmacology (medical), Settore MED/12 - Gastroenterologia, Liver Diseases, Graft Survival, clinical trial, Clinical Science, Middle Aged, Prognosis, 3. Good health, surgical procedures, operative, Liver, Corticosteroid, Original Article, Female, 030211 gastroenterology & hepatology, glomerular filtration rate (GFR), Immunosuppressive Agents, Glomerular Filtration Rate, medicine.drug, liver allograft function/dysfunction, medicine.medical_specialty, medicine.drug_class, Urology, Renal function, clinical research/practice, Tacrolimus, 03 medical and health sciences, medicine, Humans, Transplantation, business.industry, Original Articles, Liver Transplantation, Surgery, Calcineurin, business, liver transplantation/hepatology, liver transplantation: split, Follow-Up Studies
Abstract

DIAMOND: multicenter, 24‐week, randomized trial investigating the effect of different once‐daily, prolonged‐release tacrolimus dosing regimens on renal function after de novo liver transplantation. Arm 1: prolonged‐release tacrolimus (initial dose 0.2mg/kg/day); Arm 2: prolonged‐release tacrolimus (0.15–0.175mg/kg/day) plus basiliximab; Arm 3: prolonged‐release tacrolimus (0.2mg/kg/day delayed until Day 5) plus basiliximab. All patients received MMF plus a bolus of corticosteroid (no maintenance steroids). Primary endpoint: eGFR (MDRD4) at Week 24. Secondary endpoints: composite efficacy failure, BCAR and AEs. Baseline characteristics were comparable. Tacrolimus trough levels were readily achieved posttransplant; initially lower in Arm 2 versus 1 with delayed initiation in Arm 3. eGFR (MDRD4) was higher in Arms 2 and 3 versus 1 (p = 0.001, p = 0.047). Kaplan–Meier estimates of composite efficacy failure‐free survival were 72.0%, 77.6%, 73.9% in Arms 1–3. BCAR incidence was significantly lower in Arm 2 versus 1 and 3 (p = 0.016, p = 0.039). AEs were comparable. Prolonged‐release tacrolimus (0.15–0.175mg/kg/day) immediately posttransplant plus basiliximab and MMF (without maintenance corticosteroids) was associated with lower tacrolimus exposure, and significantly reduced renal function impairment and BCAR incidence versus prolonged‐release tacrolimus (0.2mg/kg/day) administered immediately posttransplant. Delayed higher‐dose prolonged‐release tacrolimus initiation significantly reduced renal function impairment compared with immediate posttransplant administration, but BCAR incidence was comparable., The DIAMOND study demonstrates that an initial lower dose or a delayed higher dose of prolonged‐release tacrolimus significantly reduces renal function impairment versus a higher initial dose of prolonged‐release tacrolimus administered immediately posttransplant, over 24 weeks of treatment in de novo liver transplant recipients.

Published
2015

32. Inzidenz von Narbenhernie nach Ileostomarückverlagerung bei tiefer anteriorer Rektumresektionen – eine klinische und radiologische Analyse

Author

Juratli, M, Habbe, N, Hannes, S, El youzouri, H, Bechstein, WO, and Woeste, G

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die Anlage eines protektiven doppelläufigen Ileostomas im Rahmen tiefer anteriorer Rektumresektionen bei Patienten mit einem Rektumkarzinom hat sich als Standartverfahren etabliert und führt zu einer deutlichen Senkung klinisch apparenter Anastomoseninsuffizienzen. Bezügliche[for full text, please go to the a.m. URL], 132. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2015
Full Text
View/download PDF

33. Ist R0 gleich R0? Einfluss des Resektionsrandabstandes auf das Überleben nach Leberteilresektionen bei kolorektalen Lebermetastasen

Author

Schreckenbach, T, El Youzouri, H, Woeste, G, Bechstein, WO, Schnitzbauer, A, and Ulrich, F

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die kurative Resektion kolorektaler Lebermetastasen (CRLM) bietet Patienten mit oligometastatischen Befunden eine signifikante Prognoseverbesserung. In Zeiten effektiver perioperativer Therapien gilt ein Resektionsrandabstand von kleiner als 1 cm als kurativ. Ziel dieser Studie war es, den[for full text, please go to the a.m. URL], 132. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2015
Full Text
View/download PDF

34. Radiologische Diagnostik des Rektumkarzinoms: Nachsorge und Rezidivdiagnostik

Author

W. Pegios, Bechstein Wo, T. J. Vogl, and J Floeter

Subjects
medicine.medical_specialty, PET-CT, medicine.diagnostic_test, business.industry, Rectum, Immunoscintigraphy, Functional imaging, medicine.anatomical_structure, Radiological weapon, Rectal carcinoma, Biopsy, medicine, Radiology, Nuclear Medicine and imaging, Radiology, Tomography, business
Abstract

Rectal carcinoma is one of the most frequent malignant tumors in adulthood. Not only after total resection but also after partial resection of the tumor with postoperative radiochemotherapy a sufficient follow-up is necessary to diagnose recurrent rectal cancer as early as possible. Various guidelines suggest different intervals for physical examinations and diagnostic methods depending on the initial tumor stage. In addition to routine examinations, the physician can choose between CT, MRI, endosonography and functional imaging techniques such as PET and immunoscintigraphy for further evaluation if a recurrent rectal cancer is suspected. Multiple studies and meta-analyses show the differences in the specificity and sensitivity of the diagnostic methods in the detection of lymph nodes, metastases, and local tumor infiltration. Endosonography and endorectal MRI show very good results in staging local tumor infiltration. However, obstructive lesions can inhibit an adequate examination. CT provides prompt and convincing results in the evaluation of the metastases. Most of the time the tumor can be identified but the lack of detailed imaging makes it hard to perform sufficient staging. Additionally image-guided biopsy can be performed. Immunoscintigraphy and PET have a high specificity because they take advantage of the tumor's metabolism. The introduction of the PET-CT has eliminated the disadvantage of low image resolution. In addition to the detection of small nodular pulmonary metastases, MRI with its "phased-array" coils is another excellent tool for the diagnosis of recurrent rectal cancer and search for metastases. This review shows the advantages and disadvantages of each diagnostic method in the visualization of recurrent rectal cancer.

Published
2006
Full Text
View/download PDF

40. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

Author

Geissler, E, Schnitzbauer, A, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, van Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, de Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Mirza, D, Otto, G, Mazzaferro, V, Neuhaus, P, Schlitt, H, Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrion VS, Jamieson N, Scholz T, Colledan M, Fandrich F, Becker T, Soderdahl G, Chazouilleres O, Makisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Konigsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ, Geissler, E, Schnitzbauer, A, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, van Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, de Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Mirza, D, Otto, G, Mazzaferro, V, Neuhaus, P, Schlitt, H, Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrion VS, Jamieson N, Scholz T, Colledan M, Fandrich F, Becker T, Soderdahl G, Chazouilleres O, Makisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Konigsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, and Schlitt HJ

Abstract

Background.We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC). Methods. In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-To-Treat (ITT) analysis was conducted after 8 years. Overall survival (OS) was a secondary endpoint. Results. Recurrence-free survival was 64.5% in group A and 70.2% in group B at study end, this difference was not significant (P = 0.28; hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62; 1.15). In a planned analysis of RFS rates at yearly intervals, group B showed better outcomes 3 years after transplantation (HR, 0.7; 95% CI, 0.48-1.00). Similarly, OS (P = 0.21; HR, 0.81; 95% CI, 0.58-1.13) was not statistically better in group B at study end, but yearly analyses showed improvement out to 5 years (HR, 0.7; 95% CI, 0.49-1.00). Interestingly, subgroup (Milan Criteria-based) analyses revealed that low-risk, rather than high-risk, patients benefited most fromsirolimus; furthermore, younger recipients (age ≤60) also benefited, as well sirolimus monotherapy patients. Serious adverse event numbers were alike in groups A (860) and B (874). Conclusions. Sirolimus in LTx recipients with HCC does not improve long-Term RFS beyond 5 years. However, a RFS and OS benefit is evident in the first 3 to 5 years, especially in low-risk patients. This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC.

Published
2016

41. Liver Transplantation for Hepatic Trauma: A Study From the European Liver Transplant Registry

Author

Krawczyk, M, Grat, M, Adam, R, Polak, W, Klempnauer, J, Pinna, A, Di Benedetto, F, Filipponi, F, Senninger, N, Foss, A, Rufian-Pena, S, Bennet, W, Pratschke, J, Paul, A, Settmacher, U, Rossi, G, Salizzoni, M, Fernandez-Selles, C, de Rituerto, S, Gomez-Bravo, M, Pirenne, J, Detry, O, Majno, P, Nemec, P, Bechstein, W, Bartels, M, Nadalin, S, Pruvot, F, Mirza, D, Lupo, L, Colledan, M, Tisone, G, Ringers, J, Daniel, J, Torra, R, Gonzalez, E, Canizares, R, Martinez, V, Rodriguez, F, Yilmaz, S, Remiszewski, P, Krawczyk M, Grat M, Adam R, Polak WG, Klempnauer J, Pinna A, Di Benedetto F, Filipponi F, Senninger N, Foss A, Rufian-Pena S, Bennet W, Pratschke J, Paul A, Settmacher U, Rossi G, Salizzoni M, Fernandez-Selles C, de Rituerto STM, Gomez-Bravo MA, Pirenne J, Detry O, Majno PE, Nemec P, Bechstein WO, Bartels M, Nadalin S, Pruvot FR, Mirza DF, Lupo L, Colledan M, Tisone G, Ringers J, Daniel J, Torra RC, Gonzalez EM, Canizares RB, Martinez VCM, Rodriguez FSJ, Yilmaz S, Remiszewski P, Krawczyk, M, Grat, M, Adam, R, Polak, W, Klempnauer, J, Pinna, A, Di Benedetto, F, Filipponi, F, Senninger, N, Foss, A, Rufian-Pena, S, Bennet, W, Pratschke, J, Paul, A, Settmacher, U, Rossi, G, Salizzoni, M, Fernandez-Selles, C, de Rituerto, S, Gomez-Bravo, M, Pirenne, J, Detry, O, Majno, P, Nemec, P, Bechstein, W, Bartels, M, Nadalin, S, Pruvot, F, Mirza, D, Lupo, L, Colledan, M, Tisone, G, Ringers, J, Daniel, J, Torra, R, Gonzalez, E, Canizares, R, Martinez, V, Rodriguez, F, Yilmaz, S, Remiszewski, P, Krawczyk M, Grat M, Adam R, Polak WG, Klempnauer J, Pinna A, Di Benedetto F, Filipponi F, Senninger N, Foss A, Rufian-Pena S, Bennet W, Pratschke J, Paul A, Settmacher U, Rossi G, Salizzoni M, Fernandez-Selles C, de Rituerto STM, Gomez-Bravo MA, Pirenne J, Detry O, Majno PE, Nemec P, Bechstein WO, Bartels M, Nadalin S, Pruvot FR, Mirza DF, Lupo L, Colledan M, Tisone G, Ringers J, Daniel J, Torra RC, Gonzalez EM, Canizares RB, Martinez VCM, Rodriguez FSJ, Yilmaz S, and Remiszewski P

Abstract

Background. Liver transplantation is the most extreme form of surgical management of patients with hepatic trauma, with very limited literature data supporting its use. The aim of this study was to assess the results of liver transplantation for hepatic trauma. Methods. This retrospective analysis based on European Liver Transplant Registry comprised data of 73 recipients of liver transplantation for hepatic trauma performed in 37 centers in the period between 1987 and 2013. Mortality and graft loss rates at 90 days were set as primary and secondary outcome measures, respectively. Results. Mortality and graft loss rates at 90 days were 42.5% and 46.6%, respectively. Regarding general variables, cross-clamping without extracorporeal veno-venous bypass was the only independent risk factor for both mortality (P = 0.031) and graft loss (P = 0.034). Regarding more detailed factors, grade of liver trauma exceeding IV increased the risk of mortality (P = 0.005) and graft loss (P = 0.018). Moreover, a tendency above the level of significance was observed for the negative impact of injury severity score (ISS) on mortality (P = 0.071). The optimal cutoff for ISS was 33, with sensitivity of 60.0%, specificity of 80.0%, positive predictive value of 75.0%, and negative predictive value of 66.7%. Conclusions. Liver transplantation seems to be justified in selected patients with otherwise fatal severe liver injuries, particularly in whom cross-clamping without extracorporeal bypass can be omitted. The ISS cutoff less than 33 may be useful in the selection process.

Published
2016

45. Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry

Author

Adam, R, Karam, V, Delvart, V, Trunecka, P, Samuel, D, Bechstein, W, Nemec, P, Tisone, G, Klempnauer, J, Rossi, M, Rummo, O, Dokmak, S, Krawczyk, M, Pratschke, J, Kollmar, O, Boudjema, K, Colledan, M, Ericzon, B, Mantion, G, Baccarani, U, Neuhaus, P, Paul, A, Bachellier, P, Zamboni, F, Hanvesakul, R, Muiesan, P, Adam R, Karam V, Delvart V, Trunecka P, Samuel D, Bechstein WO, Nemec P, Tisone G, Klempnauer J, Rossi M, Rummo OO, Dokmak S, Krawczyk M, Pratschke J, Kollmar O, Boudjema K, Colledan M, Ericzon BG, Mantion G, Baccarani U, Neuhaus P, Paul A, Bachellier P, Zamboni F, Hanvesakul R, Muiesan P, Adam, R, Karam, V, Delvart, V, Trunecka, P, Samuel, D, Bechstein, W, Nemec, P, Tisone, G, Klempnauer, J, Rossi, M, Rummo, O, Dokmak, S, Krawczyk, M, Pratschke, J, Kollmar, O, Boudjema, K, Colledan, M, Ericzon, B, Mantion, G, Baccarani, U, Neuhaus, P, Paul, A, Bachellier, P, Zamboni, F, Hanvesakul, R, Muiesan, P, Adam R, Karam V, Delvart V, Trunecka P, Samuel D, Bechstein WO, Nemec P, Tisone G, Klempnauer J, Rossi M, Rummo OO, Dokmak S, Krawczyk M, Pratschke J, Kollmar O, Boudjema K, Colledan M, Ericzon BG, Mantion G, Baccarani U, Neuhaus P, Paul A, Bachellier P, Zamboni F, Hanvesakul R, and Muiesan P

Abstract

This study was a retrospective analysis of the European Liver Transplant Registry (ELTR) performed to compare long-term outcomes with prolonged-release tacrolimus versus tacrolimus BD in liver transplantation (January 2008-December 2012). Clinical efficacy measures included univariate and multivariate analyses of risk factors influencing graft and patient survival at 3 years posttransplant. Efficacy measures were repeated using propensity score-matching for baseline demographics. Patients with <1 month of follow-up were excluded from the analyses. In total, 4367 patients (prolonged-release tacrolimus: n = 528; BD: n = 3839) from 21 European centers were included. Tacrolimus BD treatment was significantly associated with inferior graft (risk ratio: 1.81; p = 0.001) and patient survival (risk ratio: 1.72; p = 0.004) in multivariate analyses. Similar analyses performed on the propensity score-matched patients confirmed the significant survival advantages observed in the prolonged-release tacrolimus- versus tacrolimus BD-treated group. This large retrospective analysis from the ELTR identified significant improvements in long-term graft and patient survival in patients treated with prolonged-release tacrolimus versus tacrolimus BD in primary liver transplant recipients over 3 years of treatment. However, as with any retrospective registry evaluation, there are a number of limitations that should be considered when interpreting these data.

Published
2015

47. Volumetrische und morphologische CT-Parameter zur Prognoseabschätzung und Therapiekontrolle des hepatozellulären Karzinoms unter arterieller Chemoembolisation

Author

Schröder H, A. Scholz, M. G. Mack, R. Felix, Th. Vogl, Trapp M, Bechstein Wo, W. Pegios, Keck W, and Peter Neuhaus

Subjects
Cisplatin, Adriblastin, medicine.medical_specialty, business.industry, medicine.medical_treatment, Single injection, medicine.disease, Solitary lesion, Survival probability, Hepatocellular carcinoma, medicine, Lipiodol, Radiology, Nuclear Medicine and imaging, Embolization, Radiology, business, medicine.drug
Abstract

PURPOSE: To evaluate volumetric CT data as a guide for indication and assessment of prognosis for transarterial chemo-embolisation (TAE) of hepatocellular carcinomas (HCC). MATERIAL AND METHOD: 74 patients with HCC were treated with repeated TAE. 50 mg Adriblastin/m2 body surface, 50 mg cisplatin/m2 body surface and 10 ml lipiodol were combined with 2-10 ml Spherex and injected selectively (25 cases) or superselectively (49 cases); in 28 patients a single injection and in 46 patients multiple injections were used. RESULTS: CT findings before and after the procedure showed a solitary lesion in 17 patients, two lesions in 18 patients and in 39 patients there were three or more lesions. Mean expectation of life was 523 days (median = 372 days; 57% of one year survival probability). In 29 patients with > 75% lipiodol retention, mean survival was 819 days; in 17 patients with 75% intra-tumoral lipiodol retention.

Published
1997
Full Text
View/download PDF

48. Vaskularisationsmuster in fokalen Leberläsionen: Vergleich der nativen und signalverstärkten amplitudenmodulierten Farbduplexsonographie

Author

S. Weber, W. Steger, N. Hosten, W. Zendel, Arne-Jörn Lemke, Bechstein Wo, R. Felix, T. J. Vogl, and S. Venz

Subjects
Duplex ultrasonography, Pathology, medicine.medical_specialty, Small diameter, business.industry, Ultrasound, Focal nodular hyperplasia, medicine.disease, Feeding artery, Peripheral veins, Power doppler, Microbubbles, medicine, Radiology, Nuclear Medicine and imaging, business
Abstract

PURPOSE Morphology of focal liver lesions was studied by power Doppler. Plain images and images after i.v. application of galactose-based microbubbles (Levovist, Schering AG) were compared. METHODS 21 patients with focal liver lesions were studied by power Doppler before and after application of the signal enhancer. RESULTS In lesions that showed short pulsations in plain studies, vascular structures were visible after application of the signal enhancer. In hepatocellular carcinomas, multiple arteries with small diameter became visible. Peripheral veins were detected in metastases. A large feeding artery was detected in 1/2 haemangiomas with flow and in a focal nodular hyperplasia. CONCLUSION In comparison to plain amplitude-modulated colour-coded duplex ultrasound, vascular patterns of focal liver lesions were more clearly visible after injection of a signal-enhancer.

Published
1997
Full Text
View/download PDF

49. Der Hautverschluss in Tabakbeutelnaht-Technik führt zur Reduktion der Wundinfekte bei der Ileostoma-Rückverlagerung

Author

Habbe, N, Hannes, S, Liese, J, Strey, C, and Bechstein, WO

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Wundinfektionen nach Ileostoma-Rückverlagerung sind ein häufiges Problem. Verschiedene Techniken wurden entwickelt, um diesem Problem zu begegnen. Der Hautverschluss in intrakutaner Tabakbeutelnaht-Technik wurde 2007 erstmalig publiziert und scheint zur Reduktion der Wundinfekte[for full text, please go to the a.m. URL], 130. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2013
Full Text
View/download PDF

50. Kein Einfluss der neoadjuvanten Antikörpertherapie auf die postoperative Morbidität nach Leberteilresektion bei Patienten mit kolorektalen Lebermetastasen

Author

Schreckenbach, T, Woeste, G, Holzer, K, and Bechstein, WO

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Im Rahmen von Studien wie der Crystal-Studie konnte ein signifikant verbessertes Überleben für Patienten mit kolorektalen Lebermetastasen bei einer Therapie mit Antikörpern nachgewiesen werden. Anhand unserer Daten soll gezeigt werden, dass für Patienten mit einer neoadjuvanten[for full text, please go to the a.m. URL], 130. Kongress der Deutschen Gesellschaft für Chirurgie

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results